Updating results

402 results

Sort: Relevance | Date

Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Technology appraisal guidance In development

Masitinib for treating amyotrophic lateral sclerosis [ID967]

In development [GID-TA10157] Expected publication date: TBC

Technology appraisal guidance In development

Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Technology appraisal guidance In development

DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Technology appraisal guidance In development

Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Technology appraisal guidance In development

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Technology appraisal guidance In development

Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Technology appraisal guidance In development

Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Technology appraisal guidance In development

Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - lorcaserin [ID337]

In development [GID-TAG420] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]

In development [GID-TA10047] Expected publication date: TBC

Technology appraisal guidance In development

Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Pulmonary arterial hypertension (adults) - drugs [ID12]

In development [GID-TAG382] Expected publication date: TBC

Technology appraisal guidance In development

Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

In development [GID-TA10140] Expected publication date: TBC

Technology appraisal guidance In development

Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Technology appraisal guidance In development

Atherothrombotic events - vorapaxar [ID616]

In development [GID-TAG493] Expected publication date: TBC

Technology appraisal guidance In development

Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Technology appraisal guidance In development

T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Technology appraisal guidance In development